These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17427501)

  • 21. Hepatitis C.
    Burra P
    Semin Liver Dis; 2009 Feb; 29(1):53-65. PubMed ID: 19235659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime.
    Blonsky JJ; Harrison SA
    Aliment Pharmacol Ther; 2008 May; 27(10):855-65. PubMed ID: 18315584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation.
    Botha JF; Thompson E; Gilroy R; Grant WJ; Mukherjee S; Lyden ER; Fox IJ; Sudan DL; Shaw BW; Langnas AN
    Liver Int; 2007 Aug; 27(6):758-63. PubMed ID: 17617118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spectrum of histological features in non-alcoholic fatty liver disease.
    Vasdev N; Kakati AG; Saigal S; Nayak NC
    Natl Med J India; 2007; 20(6):282-7. PubMed ID: 18335793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The natural history of hepatitis C cirrhosis after liver transplantation.
    Firpi RJ; Clark V; Soldevila-Pico C; Morelli G; Cabrera R; Levy C; Machicao VI; Chaoru C; Nelson DR
    Liver Transpl; 2009 Sep; 15(9):1063-71. PubMed ID: 19718647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
    Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
    Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.
    Rodríguez-Torres M; Govindarajan S; Solá R; Clumeck N; Lissen E; Pessôa M; Buggisch P; Main J; Depamphilis J; Dieterich DT
    J Hepatol; 2008 May; 48(5):756-64. PubMed ID: 18314217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?
    Rodríguez-Torres M; Gonzalez-Garcia J; Bräu N; Solá R; Moreno S; Rockstroh J; Smaill F; Mendes-Correa MC; DePamphilis J; Torriani FJ;
    J Med Virol; 2007 Jun; 79(6):694-700. PubMed ID: 17457912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral hepatitis and HIV coinfection.
    Sulkowski MS
    J Hepatol; 2008 Feb; 48(2):353-67. PubMed ID: 18155314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.
    Rai RR; Mathur A; Mathur D; Udawat HP; Nepalia S; Nijhawan S; Mathur A
    Trop Gastroenterol; 2007; 28(1):19-23. PubMed ID: 17896605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C.
    Raffa G; Maimone S; Cargnel A; Santantonio T; Antonucci G; Massari M; Schiavini M; Caccamo G; Pollicino T; Raimondo G
    AIDS; 2007 Oct; 21(16):2171-5. PubMed ID: 18090043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic steatosis in chronic hepatitis B: contributing factors and effect on fibrosis.
    Elloumi H; Hefaiedh R; Gargouri D; Chedly-Debbiche A; Khayat O; Bel Hadj N; Kharrat J; Ghorbel A
    Tunis Med; 2008 Nov; 86(11):1000-3. PubMed ID: 19213493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    Pineda JA; Santos J; Rivero A; Abdel-Kader L; Palacios R; Camacho A; Lozano F; Macías J;
    J Antimicrob Chemother; 2008 Apr; 61(4):925-32. PubMed ID: 18276600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of chronic hepatitis B: recommendations from an Italian workshop.
    Carosi G; Rizzetto M
    Dig Liver Dis; 2008 Aug; 40(8):603-17. PubMed ID: 18499540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.
    Burra P; Loreno M; Russo FP; Germani G; Galligioni A; Senzolo M; Cillo U; Zanus G; Fagiuoli S; Rugge M
    Liver Transpl; 2009 Jun; 15(6):619-28. PubMed ID: 19479805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver transplantation in HIV/hepatitis co-infection.
    Miro JM; Aguero F; Laguno M; Tuset M; Cervera C; Moreno A; Garcia-Valdecasas JC; Rimola A;
    J HIV Ther; 2007 Mar; 12(1):24-35. PubMed ID: 17589393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunology of hepatitis B and hepatitis C virus infections.
    Boonstra A; Woltman AM; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1049-61. PubMed ID: 19187866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.
    Peng D; Han Y; Ding H; Wei L
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1082-8. PubMed ID: 18707599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment with natural interferon (alfaferone) in clinical practice--our experience].
    Dybowska D; Halota W
    Przegl Epidemiol; 2007; 61(1):17-22. PubMed ID: 17702434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Glutathione in the treatment of chronic fatty liver diseases].
    Dentico P; Volpe A; Buongiorno R; Grattagliano I; Altomare E; Tantimonaco G; Scotto G; Sacco R; Schiraldi O
    Recenti Prog Med; 1995; 86(7-8):290-3. PubMed ID: 7569285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.